U.S. market Closed. Opens in 2 days 3 hours 43 minutes

LAB | Standard BioTools Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 2.4850 - 2.5900
52 Week Range 1.5700 - 3.16
Beta 1.60
Implied Volatility 128.55%
IV Rank 41.08%
Day's Volume 2,933,993
Average Volume 2,498,329
Shares Outstanding 383,049,000
Market Cap 984,435,930
Sector Healthcare
Industry Medical - Diagnostics & Research
IPO Date 2011-02-10
Valuation
Profitability
Growth
Health
P/E Ratio -2.57
Forward P/E Ratio N/A
EPS -1.00
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 534
Country USA
Website LAB
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
LAB's peers: MYNZ, NDRA, TRIB, STRRP, GTH, BDSX, OLK, FONR, MDXH, NOTV, BNR, SERA, LMDX, STIM, DRIO
*Chart delayed
Analyzing fundamentals for LAB we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see LAB Fundamentals page.

Watching at LAB technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on LAB Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙